Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 5 from your keywords: subject="Forespi"
cover
What is the role of roflumilast in chronic obstructive pulmonary disease?
Comment Share
Lau C

Roflumilast has been shown to reduce rates of acute exacerbation in patients with severe chronic obstructive pulmonary disease (COPD), ie, forced expiratory volume in 1 second (FEV1) less than 50% with symptoms of chronic bronchitis and a history of exacerbations. Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor that acts on airway smooth muscle cells and various inflammatory …

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Roflumilast: A Review in COPD
Comment Share
Garnock-Jones KP

Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary inflammation and improves disease symptoms in patients with severe chronic obstructive pulmonary disease (COPD). This article reviews the pharmacological properties of roflumilast and its clinical efficacy and tolerability in patients with COPD. Roflumilast is an effective treatment in patients…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Roflumilast: In Chronic Obstructive Pulmonary Disease
Comment Share
Sanford M

Roflumilast is an orally administered, selective phosphodiesterase 4 inhibitor that is a novel treatment for patients with severe chronic obstructive pulmonary disease (COPD). Across four randomized, double-blind, multinational trials in patients with moderate to severe or severe COPD, roflumilast 500 microg/day produced significantly greater improvements from baseline than placebo in pre- and …

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Eff ect of roflumilast on exacerbations in patients with severe chronic obstr…
Comment Share
Martinez FJ

Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. Its eff ect in patients using fi xed combinations of inhaled corticosteroids and longacting β2 agonists is unknown. We postulated that rofl umilast would reduce exacerbations in patients with severe chronic obstructive pulmonary disease at risk for exacerbations, even in combination with inhaled co…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation …
Comment Share
Bateman ED

The oral, selective phosphodiesterase type-4 inhibitor roflumilast reduces exacerbations and improves lung function in patients with severe-to-very severe chronic obstructive pulmonary disease (COPD). We investigated the efficacy and safety of roflumilast used concomitantly with long-acting b2- agonists (LABAs) to reduce exacerbations, and the influence of exacerbation history. Pooled data wer…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-